This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.


Lina Gugucheva
CBO at Northern Biologics


Lina Gugucheva joined Northern Biologics as Chief Business Offer in November 2019.  Prior to joining Northern, Ms. Gugucheva served as Vice President, Business Development & Strategy at IFM Therapeutics. At IFM, Ms. Gugucheva led the structuring, negotiation and execution of multiple debt and equity financings in excess of $100M across multiple IFM subsidiaries. Ms. Gugucheva also spearheaded IFM’s business development efforts, leading IFM’s negotiations for the successful $1.58B sale of IFM Tre, IFM’s NLRP3 antagonist-focused subsidiary, to Novartis in May 2019, as well as the $880M collaboration and exclusive option agreement between Novartis and IFM Due, IFM’s subsidiary, to develop novel immunotherapies inhibiting the cGAS/STING pathway in August 2019.

Ms. Gugucheva began her career as a life sciences transactional associate at the law firm of Covington & Burling. Ms. Gugucheva was then Vice President, Investments & Counsel at Royalty Pharma where she negotiated a series of transactions including the $2.85 billion purchase of a royalty interest on sales of the multiple sclerosis drug, TYSABRI®. Ms. Gugucheva holds a J.D. from Harvard Law School and a B.A. in molecular biology and political science from New York University.

Agenda Sessions

  • Fireside Chat: Maximizing Value in an M&A